Assessment of the safety and biodistribution of a regulated AAV2 gene transfer vector after delivery to murine submandibular glands.
暂无分享,去创建一个
T. Clackson | J. Chiorini | V. Rivera | B. Baum | M. Vallant | R. Irwin | C. Zheng | S. Afione | M. Wenk | A. Nyska | A. Voutetakis | Benjamin A Goldstein | M. Boyle
[1] G. Illei,et al. Transient detection of E1‐containing adenovirus in saliva after the delivery of a first‐generation adenoviral vector to human parotid gland , 2010, The journal of gene medicine.
[2] G. Illei,et al. Development of a gene transfer-based treatment for radiation-induced salivary hypofunction. , 2010, Oral oncology.
[3] Zhijian Wu,et al. Effect of genome size on AAV vector packaging. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[4] B. Baum,et al. AAV5-mediated gene transfer to the parotid glands of non-human primates , 2010, Gene Therapy.
[5] J. Chiorini,et al. Long‐term transduction of miniature pig parotid glands using serotype 2 adeno‐associated viral vectors , 2009, The journal of gene medicine.
[6] B. Baum,et al. Sorting of transgenic secretory proteins in rhesus macaque parotid glands after adenovirus-mediated gene transfer. , 2008, Human gene therapy.
[7] J. Chiorini,et al. Extended transgene expression from a nonintegrating adenoviral vector containing retroviral elements. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[8] B. Baum,et al. Gender differences in serotype 2 adeno-associated virus biodistribution after administration to rodent salivary glands. , 2007, Human gene therapy.
[9] J. Chiorini,et al. Adeno-associated virus serotype 2-mediated gene transfer to the parotid glands of nonhuman primates. , 2007, Human gene therapy.
[10] B. Baum,et al. Enhanced transduction of mouse salivary glands with AAV5-based vectors , 2006, Gene Therapy.
[11] J. Rasko,et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.
[12] T. Clackson,et al. Rapamycin control of transgene expression from a single AAV vector in mouse salivary glands , 2006, Gene Therapy.
[13] Ioannis Bossis,et al. Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders. , 2005, The Journal of endocrinology.
[14] P. Tak,et al. Immune responses following salivary gland administration of recombinant adeno‐associated virus serotype 2 vectors , 2005, The journal of gene medicine.
[15] L. Rozamus,et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. , 2005, Blood.
[16] Jianghuai Wang,et al. Salivary glands: novel target sites for gene therapeutics. , 2004, Trends in molecular medicine.
[17] P. Aebischer,et al. Salivary glands and gene therapy: the mouth waters , 2004, Gene Therapy.
[18] T. Clackson,et al. 1048. Long-Term Regulated Gene Expression in Non-Human Primates Using a Single Non-Recombinogenic AAV Vector , 2004 .
[19] B. Baum,et al. Rapamycin control of exocrine protein levels in saliva after adenoviral vector-mediated gene transfer , 2004, Gene Therapy.
[20] I. Bossis,et al. Reengineered salivary glands are stable endogenous bioreactors for systemic gene therapeutics. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[21] Jaap Goudsmit,et al. Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors , 2003, Journal of Clinical Microbiology.
[22] Lili Wang,et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. , 2002, The Journal of clinical investigation.
[23] R. Herzog,et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.
[24] B. Baum,et al. Gene transfer to salivary glands. , 2002, International review of cytology.
[25] Theresa A. Storm,et al. Recruitment of Single-Stranded Recombinant Adeno-Associated Virus Vector Genomes and Intermolecular Recombination Are Responsible for Stable Transduction of Liver In Vivo , 2000, Journal of Virology.
[26] Alan McClelland,et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.
[27] James M. Wilson,et al. Humoral Immunity to Adeno-Associated Virus Type 2 Vectors following Administration to Murine and Nonhuman Primate Muscle , 2000, Journal of Virology.
[28] B. Baum,et al. Polarized secretion of transgene products from salivary glands in vivo. , 1999, Human gene therapy.
[29] V. Rivera,et al. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[30] D. Bohl,et al. Structure of Adeno-Associated Virus Vector DNA following Transduction of the Skeletal Muscle , 1999, Journal of Virology.
[31] S. Rothman,et al. The endocrine secretion of mammalian digestive enzymes by exocrine glands. , 1999, American journal of physiology. Endocrinology and metabolism.
[32] D. Grimm,et al. Novel tools for production and purification of recombinant adenoassociated virus vectors. , 1998, Human gene therapy.
[33] P. Fan,et al. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. , 1996, Human gene therapy.
[34] B. Baum,et al. Evidence for the systemic delivery of a transgene product from salivary glands. , 1996, Human gene therapy.
[35] Shannon R. Magari,et al. A humanized system for pharmacologic control of gene expression , 1996, Nature Medicine.
[36] R. Crystal,et al. Direct in vivo adenovirus-mediated gene transfer to salivary glands. , 1994, The American journal of physiology.
[37] P. Felgner,et al. Gene therapeutics , 1991, Nature.